is metformin a glp 1 receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Glucagon-like peptide-1 receptor agonists –

GLP-1 is quickly degraded by the dipeptidyl peptidase 4 (DPP-4) enzyme, making the plasma half-life 1-2 minutes

Importantly, a substantial number of patients had multiple reasons noted for stopping (21%), underscoring the complexity of real-world medication use and the challenges patients face when using these therapies

This framework offers a structured way to evaluate how emerging therapies may influence biological aging

NG28 Type 2 diabetes in adults Epidemiological report on SGLT-2 uptake

Clinical Trial Results: Tirzepatide (All Forms Mounjaro, Zepbound, Compounded): Because the active ingredient is identical, effectiveness is the same: SURMOUNT-1 Trial Results (72 weeks): 15 mg dose: 22.5% average body weight loss 10 mg dose: 21.4% average body weight loss 5 mg dose: 15.0% average body weight loss 96% of patients lost at least 5% of body weight 89% of patients lost at least 10% of body weight 63% of patients lost at least 20% of body weight Real-World Effectiveness: Compounded tirzepatide produces identical results to brand-name because its the same molecule at the same doses